RemeGen Co., Ltd. (HKG:9995)
Hong Kong
· Delayed Price · Currency is HKD 26.50
-0.30 (-1.12%)
Apr 3, 2025, 4:08 PM HKT
RemeGen Revenue
In the year 2024, RemeGen had annual revenue of 1.72B CNY with 58.40% growth. RemeGen had revenue of 506.53M in the quarter ending December 31, 2024, with 61.58% growth.
Revenue
1.72B CNY
Revenue Growth
+58.40%
P/S Ratio
7.81
Revenue / Employee
474.52K CNY
Employees
3,615
Market Cap
21.44B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Alibaba Health Information Technology | 31.39B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |